The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular testing for BRAF V600 mutations in the BRIM-2 trial of the BRAF inhibitor vemurafenib in metastatic melanoma.
K. J. Bloom
Employment or Leadership Position - Clarient
S. M. Anderson
Employment or Leadership Position - LabCorp
Stock Ownership - LabCorp
R. C. Schilling
Employment or Leadership Position - Roche
J. R. Lee
Consultant or Advisory Role - Roche
H. Halait
Employment or Leadership Position - Roche
S. Cheng
Employment or Leadership Position - Roche
Stock Ownership - Roche
R. A. Langland
Employment or Leadership Position - Roche
H. J. Lawrence
Employment or Leadership Position - Roche